The first and only fully human biologic that directly inhibits interleukin-17A has been granted a positive opinion by the Committee for Medicinal Products for Human Use (CHMP).
List view / Grid view
Cosentyx (secukinumab) is a human IgG1κ monoclonal antibody that binds to the protein interleukin (IL)-17A, and is manufactured by Novartis Pharma AG for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis.
It targets member A form of the cytokine family of interleukin 17, severely inhibiting its functioning. On January 21, 2015, the United States, the federal Food and Drug Administration announced that it had approved secukinumab to treat adults with moderate-to-severe plaque psoriasis. On January 15, 2016, the United States, the federal Food and Drug Administration announced that it had approved secukinumab to treat adults with ankylosing spondylitis, and psoriatic arthritis.
Cosentyx® resulted in a 72 percent reduced flare risk for enthesitis-related arthritis and juvenile psoriatic arthritis in a Phase III study.
Data from the Phase III JUNIPERA trial shows more patients with juvenile idiopathic arthritis achieved and maintained improvements in joint symptoms with Cosentyx® (secukinumab).
In the trial, 57 percent of patients with moderate to severe psoriasis treated with 120mg of sonelokimab achieved total skin clearance in 24 weeks.
Cosentyx®, a treatment for an inflammatory disease has met its primary endpoints in patients during a Phase III trial.
The FDA has approved the inclusion of new evidence that Cosentyx significantly slows the progression of joint structural damage..
Novartis’ Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause
15 March 2017 | By Niamh Marriott, Junior Editor
Moderate-to-severe psoriasis patients treated with Cosentyx (secukinumab) rapidly regain clear skin following relapse during a treatment pause...
31 October 2016 | By Niamh Louise Marriott, Digital Content Producer
Novartis has been awarded the 2016 Prix Galien USA Award "Discovery of the Decade" Award for Best Pharmaceutical Product for the drug Gleevec, as well as...
4 October 2016 | By Niamh Louise Marriott, Digital Content Producer
The aim of Novartis' plaque psoriasis treatment is clear skin and was achieved by 68.5% of patients at Year 1 and this high rate was maintained to Year 4...
29 September 2016 | By Niamh Louise Marriott, Digital Content Producer
NICE are recommending it as an option to treat adults with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy...
4 August 2016 | By National Institute for Health and Care Excellence (NICE)
The National Institute for Health and Care Excellence (NICE) has recommended innovative new drug secukinumab for treating ankylosing spondylitis, a type of arthritis that mainly affects the back....
11 July 2016 | By Victoria White, Digital Content Producer
The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib...
8 June 2016 | By Victoria White, Digital Content Producer
Long-term analyses suggest Cosentyx may lead to higher responses than Humira in improving signs and symptoms of ankylosing spondylitis and psoriatic arthritis...
New late-breaking data from Novartis’ head-to-head CLEAR study demonstrates that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance (PASI 90 response) at 52 weeks for adults living with moderate-to-severe psoriasis.